AIM: To evaluate the time to and factors associated with treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. METHODS: In a retrospective analysis using a large US electronic medical record database, eligible patients included those with type 2 diabetes and an HbA(1c) of ≥7.0% or at least two fasting blood glucose levels of ≥126 mg/dl while on metformin monotherapy for at least 6 months within the period of 1 January 1997 to 31 December 2008. Time to treatment intensification was calculated as the time between index date (date on which HbA(1c) ≥ 7% after metformin monotherapy for at least 6 months) and first prescription for additional antihyperglycaemic agent during follow-up period. All patients were required to have data for at least 12 months prior to and following the index date. A Cox proportional hazards model was employed to determine patient baseline characteristics associated with time to treatment intensification. RESULTS: Of the 12 566 patients identified, mean age at index date was 63 years and 51% were female. Mean index HbA(1c) was 8.0% overall, with 66, 19 and 15% of patients having an index HbA(1c) of 7 to <8%, 8 to <9% and ≥9%, respectively. Median time to treatment intensification was 14.0 months overall and 19.0, 8.7 and 4.5 months for patients with index HbA(1c) of 7 to <8%, 8 to <9% and ≥9%, respectively. Factors associated with treatment intensification included higher index HbA(1c) , younger age, higher Charlson co-morbidity index, metformin daily dose ≥ 1500 mg and later index date (all p < 0.05). CONCLUSIONS: In US clinical practice, median time to receive additional antihyperglycaemic medication is more than 1 year for patients with type 2 diabetes who failed metformin monotherapy.
AIM: To evaluate the time to and factors associated with treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. METHODS: In a retrospective analysis using a large US electronic medical record database, eligible patients included those with type 2 diabetes and an HbA(1c) of ≥7.0% or at least two fasting blood glucose levels of ≥126 mg/dl while on metformin monotherapy for at least 6 months within the period of 1 January 1997 to 31 December 2008. Time to treatment intensification was calculated as the time between index date (date on which HbA(1c) ≥ 7% after metformin monotherapy for at least 6 months) and first prescription for additional antihyperglycaemic agent during follow-up period. All patients were required to have data for at least 12 months prior to and following the index date. A Cox proportional hazards model was employed to determine patient baseline characteristics associated with time to treatment intensification. RESULTS: Of the 12 566 patients identified, mean age at index date was 63 years and 51% were female. Mean index HbA(1c) was 8.0% overall, with 66, 19 and 15% of patients having an index HbA(1c) of 7 to <8%, 8 to <9% and ≥9%, respectively. Median time to treatment intensification was 14.0 months overall and 19.0, 8.7 and 4.5 months for patients with index HbA(1c) of 7 to <8%, 8 to <9% and ≥9%, respectively. Factors associated with treatment intensification included higher index HbA(1c) , younger age, higher Charlson co-morbidity index, metformin daily dose ≥ 1500 mg and later index date (all p < 0.05). CONCLUSIONS: In US clinical practice, median time to receive additional antihyperglycaemic medication is more than 1 year for patients with type 2 diabetes who failed metformin monotherapy.
Authors: S Lane Slabaugh; Yihua Xu; Jane N Stacy; Jean C Baltz; Yunus A Meah; Jean Lian; D Chad Moretz; Jonathan R Bouchard Journal: Drugs Aging Date: 2015-02 Impact factor: 3.923
Authors: Sridharan Raghavan; Theodore Warsavage; Wenhui G Liu; Katherine Raffle; Kevin Josey; David R Saxon; Lawrence S Phillips; Liron Caplan; Jane E B Reusch Journal: Diabetes Care Date: 2022-06-02 Impact factor: 17.152
Authors: Andrew D Wiese; Christianne L Roumie; John B Buse; Herodes Guzman; Robert Bradford; Emily Zalimeni; Patricia Knoepp; Heather L Morris; William T Donahoo; Nada Fanous; Britany F Epstein; Bonnie L Katalenich; Sujata G Ayala; Megan M Cook; Katherine J Worley; Katherine N Bachmann; Carlos G Grijalva; Russell L Rothman; Rosette J Chakkalakal Journal: Pharmacoepidemiol Drug Saf Date: 2019-01-24 Impact factor: 2.890
Authors: Sam Miller; Tania Krumins; Haojin Zhou; Susan Huyck; Jeremy Johnson; Gregory Golm; Steven G Terra; James P Mancuso; Samuel S Engel; Brett Lauring Journal: Diabetes Ther Date: 2018-01-08 Impact factor: 2.945
Authors: Kamlesh Khunti; Thomas R Godec; Jesús Medina; Laura Garcia-Alvarez; Josh Hiller; Marilia B Gomes; Javier Cid-Ruzafa; Bernard Charbonnel; Peter Fenici; Niklas Hammar; Kiyoshi Hashigami; Mikhail Kosiborod; Antonio Nicolucci; Marina V Shestakova; Linong Ji; Stuart Pocock Journal: Diabetes Obes Metab Date: 2017-09-28 Impact factor: 6.577